Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Jun 23, 2021 · In this trial, the addition of 177 Lu-PSMA-617 to standard care significantly extended survival among patients with metastatic castration-resistant prostate cancer and progressive disease …
Final overall survival and safety analyses of the phase III PSMAfore ...
Abstract Background: In PSMAfore, [177 Lu]Lu-PSMA-617 (177 Lu-PSMA-617) prolonged radiographic progression-free survival (rPFS) in taxane-naive patients with metastatic castration-resistant prostate …
Lutetium-177–PSMA-617 or cabazitaxel in metastatic prostate cancer ...
May 27, 2025 · In a post-hoc analysis of circulating tumor DNA (ctDNA) features from patients with metastatic prostate cancer treated with [177Lu]Lu–PSMA-617 or cabazitaxel in the randomized …
177 Lu-PSMA-617 versus a change of androgen receptor pathway …
Sep 28, 2024 · Background [177 Lu]Lu-PSMA-617 (177 Lu-PSMA-617) prolongs radiographic progression-free survival and overall survival in patients with metastatic castration-resistant prostate …
Treatment Discontinuation in Metastatic Castration-Resistant Prostate ...
Jan 5, 2026 · ABSTRACT Background Despite the efficacy of Lutetium-177 (177 Lu)–PSMA-617 in Metastatic Castration-Resistant Prostate Cancer (mCRPC), high discontinuation rates limit its …
Lutetium-177 shows significant rPFS benefit for metastatic prostate cancer
Jan 20, 2024 · Mayo Clinic researchers found that lutetium-177 (177 Lu)-PSMA-617 prolonged radiographic progression-free survival (rPFS) in patients with PSMA-positive metastatic castration …
FDA approves expanded label for 177Lu-PSMA-617 in mCRPC
Mar 28, 2025 · The FDA has approved an expanded indication for 177 Lu-PSMA-617 (lutetium Lu 177 vipivotide tetraxetan; Pluvicto) to include use in patients with prostate-specific membrane antigen …
ESMO 2025: Discussant – Phase III Trial of [177Lu]Lu-PSMA-617 …
Arun Azad discussed PSMAddition, a phase III trial of [177 Lu]Lu-PSMA-617 combined with androgen deprivation therapy (ADT) plus an androgen receptor pathway inhibitor (ARPI) in patients with PSMA …
177Lu-PSMA-617 Plus Standard of Care Improves rPFS in PSMA …
Jan 6, 2026 · The radioligand 177Lu-PSMA-617 continues to show promise for managing patients with metastatic hormone-sensitive prostate cancer (mHSPC) in a phase 3 trial.
Pluvicto (177Lu-PSMA-617): Uses in Cancer, Side Effects, Dosage ...
May 18, 2025 · Pluvicto (lutetium Lu 177 vipivotide tetraxetan) is a targeted radioligand therapy used to treat advanced prostate cancer by delivering radiation directly to prostate-specific membrane antigen …